PMID- 12845347
OWN - NLM
STAT- MEDLINE
DCOM- 20040402
LR  - 20190607
IS  - 0835-7900 (Print)
IS  - 0835-7900 (Linking)
VI  - 17 Suppl B
DP  - 2003 Jun
TI  - What are the global response rates to Helicobacter pylori eradication therapy?
PG  - 25B-29B
AB  - OBJECTIVE: To perform a systematic review of the world literature to determine 
      current success rates of Helicobacter pylori eradication treatment. METHODS: 
      Computer searches were performed to identify systematic reviews or meta-analyses 
      of treatment studies of H pylori infection. The searches included specifications 
      for Asia, Africa, North America, South America and Europe. RESULTS: The data 
      supported the current worldwide recommendation to use proton pump inhibitor 
      (PPI)-based triple therapy with clarithromycin and either metronidazole or 
      amoxycillin. There are, however, regional differences in success rates that are 
      not completely explained by resistance to either metronidazole or amoxycillin. 
      For second-line therapy, quadruple therapy using a PPI with bismuth, 
      metronidazole and tetracycline (PPI-BMT) is superior to an alternative PPI-based 
      triple therapy. CONCLUSION: There is worldwide consensus that PPI-based triple 
      therapy, preferably with clarithromycin and amoxycillin or clarithromycin and 
      metronidazole, is used as first-line therapy. Quadruple therapy of PPI-BMT is the 
      preferred rescue medication after initial failure of therapy.
FAU - Nash, Christopher
AU  - Nash C
AD  - Department of Medicine, Dalhousie University, QE II Health Sciences Centre, 
      Victoria General Site, 1278 Tower Road, Halifax, Nova Scotia B3H 2Y9, Canada.
FAU - Fischbach, Lori
AU  - Fischbach L
FAU - Veldhuyzen van Zanten, Sander
AU  - Veldhuyzen van Zanten S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - Canada
TA  - Can J Gastroenterol
JT  - Canadian journal of gastroenterology = Journal canadien de gastroenterologie
JID - 8807867
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - F8VB5M810T (Tetracycline)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin/administration & dosage/therapeutic use
MH  - Anti-Infective Agents/administration & dosage/therapeutic use
MH  - Clarithromycin/administration & dosage/therapeutic use
MH  - Drug Resistance, Bacterial
MH  - Drug Therapy, Combination/therapeutic use
MH  - *Global Health
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Metronidazole/administration & dosage/therapeutic use
MH  - Proton Pump Inhibitors
MH  - Tetracycline/administration & dosage/therapeutic use
MH  - Treatment Outcome
RF  - 50
EDAT- 2003/07/08 05:00
MHDA- 2004/04/03 05:00
CRDT- 2003/07/08 05:00
PHST- 2003/07/08 05:00 [pubmed]
PHST- 2004/04/03 05:00 [medline]
PHST- 2003/07/08 05:00 [entrez]
AID - 10.1155/2003/720743 [doi]
PST - ppublish
SO  - Can J Gastroenterol. 2003 Jun;17 Suppl B:25B-29B. doi: 10.1155/2003/720743.